Author:
Chen Li-Tzong,Satoh Taroh,Ryu Min-Hee,Chao Yee,Kato Ken,Chung Hyun Cheol,Chen Jen-Shi,Muro Kei,Kang Won Ki,Yeh Kun-Huei,Yoshikawa Takaki,Oh Sang Cheul,Bai Li-Yuan,Tamura Takao,Lee Keun-Wook,Hamamoto Yasuo,Kim Jong Gwang,Chin Keisho,Oh Do-Youn,Minashi Keiko,Cho Jae Yong,Tsuda Masahiro,Sameshima Hiroki,Kang Yoon-Koo,Boku Narikazu
Abstract
Abstract
Background
Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein.
Methods
ATTRACTION-2 was a randomized, double-blind, placebo-controlled, phase 3 trial (49 sites; Japan, South Korea, and Taiwan). The median (min–max) follow-up period was 27.3 (24.1–36.3) months. The primary endpoint was OS. A subanalysis of OS was performed based on best overall response and tumor-programmed death ligand-1 (PD-L1) expression status.
Results
Overall, 493 of 601 screened patients were randomized (2:1) to receive nivolumab (330) or placebo (163). OS (median [95% confidence interval; CI]) was significantly longer in the nivolumab group (5.26 [4.60–6.37] vs 4.14 [3.42–4.86] months in placebo group) at the 2-year follow-up (hazard ratio [95% CI], 0.62 [0.51–0.76]; P < 0.0001). A higher OS rate was observed in the nivolumab vs placebo group at 1 (27.3% vs 11.6%) and 2 years (10.6% vs 3.2%). The OS benefit was observed regardless of tumor PD-L1 expression. Among patients with a complete or partial response (CR or PR) in the nivolumab group, the median OS (95% CI) was 26.6 (21.65—not applicable) months; the OS rates at 1 and 2 years were 87.1% and 61.3%, respectively. No new safety signals were identified.
Conclusions
Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer. The long-term survival benefit of nivolumab was most evident in patients with a CR or PR.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Gastroenterology,Oncology,General Medicine
Reference29 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.
3. Ono Pharmaceutical Co., Ltd. Press release, 22 Sep 2017. https://www.ono.co.jp/eng/news/pdf/sm_cn170922.pdf (2017). Accessed 06 Aug 2018.
4. Nam D. Opdivo adds gastric cancer to indications. Korea biomedical review. 20 Aug 2019. http://www.koreabiomed.com/news/articleView.html?idxno=2883 (2018). Accessed 11 Sep 2018.
5. Ono Pharmaceutical Co., Ltd. Press release, 23 Jan 2018. https://www.ono.co.jp/eng/news/pdf/sm_cn180123.pdf (2018). Accessed 11 Sep 2018.
Cited by
147 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献